On October 21, 2025, Q32 Bio Inc. announced that it has completed enrollment in Part B of its SIGNAL‑AA Phase 2a clinical trial evaluating bempikibart for severe or very severe alopecia areata. The company reported that the trial now includes 33 patients, exceeding the original target of approximately 20 patients.
Part B is an open‑label study that administers a 200 mg loading dose of bempikibart weekly for four weeks, followed by 200 mg every other week for 32 weeks, for a total of 36 weeks of treatment and 52 weeks of follow‑up. The trial design builds on the encouraging safety and efficacy signals seen in Part A and aims to generate data that could support progression to pivotal studies.
The enrollment milestone positions Q32 Bio to report topline data from Part B in mid‑2026, a step that could determine the company’s next development phase and provide a clearer view of bempikibart’s potential as a differentiated therapy for alopecia areata.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.